<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00699322</url>
  </required_header>
  <id_info>
    <org_study_id>KCMC08MI081</org_study_id>
    <nct_id>NCT00699322</nct_id>
  </id_info>
  <brief_title>Effect of Dipeptidyl Peptidase-IV Inhibitor and Sulfonylurea on Glucose Variability and Oxidative Stress</brief_title>
  <official_title>The Comparative Study of Dipeptidyl Peptidase-IV Inhibitor and Sulfonylurea on the Effect of Improving Glucose Variability and Oxidative Stress in Type 2 Diabetic Patients With Inadequate Glycemic Control on Metformin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Catholic University of Korea</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>MSD Korea Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The Catholic University of Korea</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research will focus on the effect of Sitagliptin on 24 hour glycemic excursion and
      improvement of oxidative stress markers compared to long acting sulphonylurea Glimepiride in
      type 2 diabetic patients with inadequate glycemic control on metformin
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sitagliptin might improve not only the mean glycemic control during study period but also 24
      hour glycemic fluctuation by restoring the physiologic pattern of insulin secretion.
      Furthermore decrease postprandial glycemic excursion should decrease the oxidative stress
      markers. Those effects might be amplified in Asian patients because of prominent early phase
      insulin secretory defects accompanied with relatively less degree of insulin resistance.
      Based on this assumption, this research will focus on the effect of Sitagliptin on 24 hour
      glycemic excursion and improvement of oxidative stress markers compared to long acting
      sulphonylurea Glimepiride in type 2 diabetic patients with inadequate glycemic control on
      metformin.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2008</start_date>
  <completion_date type="Anticipated">June 2010</completion_date>
  <primary_completion_date type="Anticipated">June 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glucose variability</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>oxidative stress markers (oxidized LDL, N-carboxymethyl-lysine(CML), nitrotyrosine, 8-iso-prostaglandinF2Î±, 8-OhDG)</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sitagliptin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Glimepiride</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin</intervention_name>
    <description>100mg P.O. per day for 1month</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Januvia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glimepiride</intervention_name>
    <description>2mg P.O. per day for 1 month</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Glimel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with type 2 diabetes

          -  duration of diabetes less than 10 years

          -  HbA1c 6.5-8.0%

          -  BMI 20-30

          -  on stable dose of metformin (more than 1000mg) for at least 2 months

        Exclusion Criteria:

          -  having oral hypoglycemic agents other than metformin

          -  using insulin

          -  serum creatinin &gt;= 1.5 mg/dL

          -  SGOT, SGPT &gt;= 90

          -  ischemic heart disease

          -  congestive heart failure (NYHA class &gt;=2)

          -  severe diabetic complication (PDR, CRF, CVA)

          -  on medication affecting glucose profile (such as steroid)

          -  infectious disease

          -  malignancy

          -  pregnant or breast-feeding woman
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kun-Ho Yoon, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kangnam St.Mary's hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kun-Ho Yoon, M.D., Ph.D.</last_name>
    <phone>82-2-590-1402</phone>
    <email>yoonk@catholic.ac.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kangnam St. Mary's hospital</name>
      <address>
        <city>Seoul</city>
        <zip>137-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Seung-Hwan Lee, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eun-Sook Kim, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kun-Ho Yoon, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol JP, Colette C. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA. 2006 Apr 12;295(14):1681-7.</citation>
    <PMID>16609090</PMID>
  </reference>
  <reference>
    <citation>Colette C, Monnier L. Acute glucose fluctuations and chronic sustained hyperglycemia as risk factors for cardiovascular diseases in patients with type 2 diabetes. Horm Metab Res. 2007 Sep;39(9):683-6. Review.</citation>
    <PMID>17846977</PMID>
  </reference>
  <verification_date>October 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 16, 2008</study_first_submitted>
  <study_first_submitted_qc>June 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2008</study_first_posted>
  <last_update_submitted>October 28, 2009</last_update_submitted>
  <last_update_submitted_qc>October 28, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 29, 2009</last_update_posted>
  <responsible_party>
    <name_title>Kun-Ho Yoon</name_title>
    <organization>Kangnam St.Mary's hospital</organization>
  </responsible_party>
  <keyword>glucose variability</keyword>
  <keyword>oxidative stress</keyword>
  <keyword>sitagliptin</keyword>
  <keyword>glimepiride</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glimepiride</mesh_term>
    <mesh_term>Sitagliptin Phosphate</mesh_term>
    <mesh_term>Dipeptidyl-Peptidase IV Inhibitors</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>December 11, 2011</submitted>
    <returned>January 13, 2012</returned>
    <submitted>August 2, 2012</submitted>
    <returned>September 4, 2012</returned>
    <submitted>February 17, 2013</submitted>
    <returned>March 20, 2013</returned>
    <submitted>July 25, 2014</submitted>
    <returned>August 13, 2014</returned>
    <submitted>September 8, 2014</submitted>
    <returned>September 12, 2014</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

